ATC Group: M01AB Acetic acid derivatives and related substances

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M01AB in the ATC hierarchy

Level
Code
Title
1
Musculo-skeletal system
2
Antiinflammatory and antirheumatic products
3
Antiinflammatory and antirheumatic products, non-steroids
4
M01AB
Acetic acid derivatives and related substances

Group M01AB contents

Code
Title
Indometacin
Sulindac
Tolmetin
Zomepirac
Diclofenac
Alclofenac
Bumadizone
Etodolac
Lonazolac
Fentiazac
Acemetacin
Difenpiramide
Oxametacin
Proglumetacin
Ketorolac
Aceclofenac
Bufexamac
Indometacin, combinations
Diclofenac, combinations

Active ingredients in M01AB

Active Ingredient
Description

Aceclofenac is a non-steroidal agent with marked anti-inflammatory and analgesic properties. The mode of action of aceclofenac is largely based on the inhibition to prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclo-oxygenase, which is involved in the production of prostaglandins.

Acemetacin is a glycolic acid ester of indomethacin and the pharmacological activity resulting from acemetacin administration in man is derived from the presence of both acemetacin and indomethacin. The precise pharmacological mode of action of acemetacin is not known. However, unlike other NSAIDs, acemetacin is only a relatively weak inhibitor of prostaglandin synthetase.

Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms.

Indometacin has anti-inflammatory, antipyretic, and analgesic effects, it is an inhibitor of prostaglandin synthetase.

Ketorolac is a non-steroidal anti-inflammatory agent demonstrating analgesic and anti-inflammatory activity. Ketorolac inhibits the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins. Ketorolac has been shown to reduce prostaglandin levels in the aqueous humour after topical ophthalmic administration.

Sulindac is a fluorinated indene with a structural resemblance to indometacin. It has analgesic, anti-inflammatory and antipyretic actions.

Related product monographs

Title
Information Source
Document Type
 
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (ZA)
Medication Package Insert (MPI)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)
Medicines Authority (MT)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (ZA)
Medication Package Insert (MPI)
Medicines Authority (MT)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (ZA)
Medication Package Insert (MPI)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (IE)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)